Significant advances have been made in understanding the genetic bases for inter-subject variability in therapeutic outcomes, including adverse drug reactions (ADRs) and drug-drug interactions (DDIs). Genetic differences impact the nature of drug-receptor interaction and the resulting pharmacodynamics (PD) or toxicodynamics (TD) of a drug. Similarly, genetic-based differences in the expression and activity of drug metabolizing enzymes and drug transporters contribute to the inter-subject variability in the pharmacokinetics (PK) and toxicokinetics (TK) of a drug Role of pharmacogenetics in adverse drug reactions Nimita Dave. drugs have been marketed with no or limited experience regarding the efficacy and safety in this population. Very few clinical trials involving children have focused on the efficacy of medicines and rarely have they covered safety. The aim of this presentation is to present findings with respect to occurrence, seriousness and type of reported ADR, therapeutic group, age and gender of the child and category of reporter. The empirical analyses were based on registration files, published articles and ADR reports
submitted to the national Danish ADR database Occurrence of adverse drug reactions in the paediatric population Lise Aagaard.
Last date updated on April, 2021